Freestone Grove Partners LP Agios Pharmaceuticals, Inc. Transaction History
Freestone Grove Partners LP
- $13.4 Trillion
- Q3 2025
A detailed history of Freestone Grove Partners LP transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 15,424 shares of AGIO stock, worth $673,257. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,424Holding current value
$673,257% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AGIO
# of Institutions
247Shares Held
63.1MCall Options Held
682KPut Options Held
890K-
Farallon Capital Management LLC San Francisco, CA5.78MShares$252 Million1.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.6MShares$245 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$212 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.71MShares$162 Million3.19% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.76MShares$121 Million1.05% of portfolio
About AGIOS PHARMACEUTICALS, INC.
- Ticker AGIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,818,000
- Market Cap $2.39B
- Description
- Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...